Dornase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dornase Alfa. Educational only — not medical advice.
Labeled uses
PULMOZYME® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Source: FDA labeling via NIH DailyMed (set d8c78a7e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.